Three Cerebrolysin doses in mild-to-moderate Alzheimer’s disease
Alvarez XA · 2006 · European Journal of Neurology
Reported findings and study design
Randomized double-blind groups received 10 mL (69), 30 mL (70), 60 mL (71) or placebo (69). Infusions were given five days weekly for four weeks, then twice weekly for eight weeks.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| ADAS-Cog at week 24 | The 10 mL arm improved (p=0.038). The 30 and 60 mL arms did not significantly improve cognition. | |
| Global clinical outcome | The abstract reports improvement across the three Cerebrolysin doses. | |
| Adverse events | The abstract describes similar proportions across study arms. |
Cognitive findings varied by dose. The abstract omits detailed score differences and adverse-event counts.
Source for these results ↗ · Reviewed 2026-11-12
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- Cognitive findings varied by dose. The abstract omits detailed score differences and adverse-event counts.
Source access
Original abstract checked for selected methods and findings.
Source reviewed 2026-11-12.
Source type: Journal publication
Citation and original source
Original source: Alvarez XA. Three Cerebrolysin doses in mild-to-moderate Alzheimer’s disease European Journal of Neurology 2006.
Molekul research summary: https://molekul.io/research/cerebrolysin-alzheimers-dose-rct-2006. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry